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An optimised assay for quantitative, high-throughput analysis of 
polysialyltransferase activity  
Sara M. Elkashef, Mark Sutherland, Laurence H. Patterson, Paul M. Loadman and Robert A. 
Falconer
* 
The polysialyltransferases are biologically important glycosyltransferase enzymes responsible for the biosynthesis of 
polysialic acid, a carbohydrate polymer that plays a critical role in the progression of several diseases, notably cancer. 
Having improved the chemical synthesis and purification of the fluorescently-labelled DMB-DP3 acceptor, we report 
optimisation and validation of a highly sensitive cell-free high-throughput HPLC-based assay for assessment of human 
polysialyltransferase activity.  
Introduction 
Polysialic acid (polySia) is a homopolymer of N-acetylneuraminic 
acid (sialic acid, Neu5Ac), which is linked specifically by α-2,8-
glycosidic bonds, and post-translationally modifies the neural cell 
adhesion molecule (NCAM).
1
 PolySia is abundantly expressed 
throughout embryonic development, but is subsequently down-
regulated during maturation and differentiation.
2, 3
 PolySia has 
received considerable interest due to its potential role in many 
biological processes, including inflammatory diseases,
4
  
neurodegenerative diseases,
5, 6
 schizophrenia,
7-10
 psychotic and 
mood disorders,
11
 autism
12
 and other related psychiatric 
disorders
13, 14
 and most notably, cancer.
15-17 
As an onco-developmental antigen, polySia is re-expressed during 
the progression of a number of malignant human tumours such as 
neuroblastoma,
18, 19
 Wilms’ tumour,
20
 medulloblastoma,
21
 
pheochromocytoma,
22
 medullary thyroid carcinoma,
23
 lung 
cancer,
15, 24
 pituitary adenomas
25
 and breast cancer.
26, 27
 In these 
tumours, NCAM polysialylation correlates with metastatic potential 
and poor prognosis and plays a key role in tumour cell migration, 
invasion and metastasis.
16, 19, 28, 29
 SiRNA knockdown of 
polysialyltransferase (polyST), which is responsible for polySia 
biosynthesis, abolishes tumour cell growth and dissemination.
29 
Despite its key role in cancer, polySia has to-date only been 
efficiently modulated by genetic manipulation, enzymatic 
digestion,
30
 or by the use of inhibitors that lack drug-like properties 
for in vivo use (inhibitors of the sialic acid biosynthesis pathway,
1, 31
 
or CMP analogues
28, 32, 33
). A major factor that has hindered 
progress in the development of novel polyST inhibitors is the lack of 
an efficient technique for high throughput, sensitive and 
quantitative assessment of human polyST enzyme activity.
34
 
Studying polySTs presents particular challenges since they are less 
catalytically active when compared to the majority of the wider 
sialyltransferase (ST) family.
35
 Furthermore, the catalytic 
mechanisms underpinning polyST function are still poorly 
understood. PolySTs are one of the few STs which predominantly 
glycosylate a specific protein.
36
 A pressing need remains for a new 
strategy to assay polyST activity.   
Several methods have been reported for the assessment of the 
activity of different mono-ST enzymes, each with significant 
shortcomings when applied more specifically to polyST activity 
measurement. These methods can be broadly divided into four 
groups: radioactive assays,
37-40
 non-radioactive assays,
41, 42
 
phosphatase-coupled assays
43
 and chemical conjugation methods.
44
 
In summary, none of these approaches is satisfactory for polyST 
analysis, requiring huge quantities of enzyme and acceptor 
proteins, at considerable cost. These assays additionally lack the 
ability to show the characteristics of the reaction product(s) in 
terms of polySia chain length (or molecular weight) in order to 
enable characterisation of enzyme activity, do not allow for high 
throughput analysis of enzyme inhibitors (primarily due to a lack of 
sensitivity) and rapid analysis of results and/or are not suitable for 
efficient analysis of the human polyST enzymes. Mammalian and 
bacterial polySTs share no significant sequence identity. Although 
they both catalyse the same reaction, different cellular 
environments and acceptor substrates are involved.
42
 
Subsequently, high throughput analysis techniques specific for the 
human enzymes must be optimised. 
Here we have utilised a non-ganglioside fluorescent acceptor to 
assess polyST activity. A trimer (degree of polymerisation, DP=3) of 
α-2,8-linked sialic acid (DP3) directly conjugated to a 1,2-diamino-
4,5-methylenedioxybenzene (DMB) label, thereby forming DMB-
DP3, has been previously reported by the Gerardy-Schahn group as 
a useful acceptor for bacterial and murine ST8SiaII enzymes.
44
 We 
have previously utilised DMB-DP3 to determine the activity of 
human polyST following inhibition by CMP (Figure 1).
28
  
In this article, we describe the optimisation of a cell-free 
chromatographic assay that enables simple, quantitative and high-
throughput analysis of human polyST. This assay enables the 
characterisation of reaction products in terms of molecular weight, 
does not depend on radioactive material nor antibodies for product 
detection and overcomes the issues of low sensitivity experienced 
with the other methodologies described above. Furthermore, it is 
cost-effective, using only minimal quantities of enzyme.  
 
 
Figure 1. The main steps of the optimised assay for the analysis of 
human polyST. 
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Experimental section 
Chemicals and reagents 
General chemicals and reagents were obtained from Sigma-Aldrich 
(Poole, UK) unless otherwise specified. Human recombinant ST8SiaII 
(EC 2.4.99; accession number Q92186, UniProtKB) was synthesised 
as described previously.
28 
DMB-DP3 labelling reaction and purification 
DMB labelling was performed as previously described.
44
 Briefly, DP3 
(10 mg/ml) was dissolved in a labelling solution (1 ml) consisting of 
DMB (20 mM), sodium hydrosulfite (40 mM) and β-
mercaptoethanol (1 M). The solution was then mixed with an equal 
volume of ice-cold trifluoroacetic acid (40 mM). The reaction 
mixture was subsequently incubated for 24 hours at 4°C. The 
derivatisation reaction was then stopped by the addition of one 
fifth reaction volume of sodium hydroxide (200 µM).  
DMB-DP3 purification by reversed phase chromatography 
A Waters 2695 alliance HPLC system operated by Masslynx software 
was used to analyse samples. Separation was achieved by reversed 
phase chromatography on a Hichrom RPB C18 column (25 cm x 4.6 
mm, 250 Å, Hichrom, UK). Chromatography was performed at 1.2 
ml/min with ammonium formate (5 mM, pH 6) (mobile phase A) 
and 55% methanol in distilled water (mobile phase B). Elution of 
DMB-DP3 was achieved with an isocratic method of 90% mobile 
phase B over 70 minutes. The separation was monitored by mass 
spectrometry (Waters ZMD, Micromass, United Kingdom), 
photodiode array detector (373, 303 and 250 nm) (Waters 2996) 
and fluorescence detector (RF-10A), (excitation 373, emission 448 
nm) all connected in series. A single fraction containing the DMB-
DP3 was collected (confirmed by detecting the molecular weight 
and comparing the retention time with a DMB-DP3 standard 
obtained from the Gerardy-Schahn group). Fractions from several 
injections were pooled and freeze-dried. The purified material was 
weighed and dissolved in water to create a 200 µM DMB-DP3 
solution and stored at -20°C. 
 
Mass spectrometric analysis 
Liquid chromatography-mass spectrometry analysis was carried out 
using a Waters ZMD (Micromass, Manchester, United Kingdom) 
single quadrupole mass spectrometer connected in series to a 
Water Alliance 2695 system. The mass spectrometer was operated 
in negative ion electrospray mode. A solvent flow of 1.2 ml/min 
(split 1:10). The cone voltage was set at 30 V. The mass spectra 
were continuously scanned from m/z 100 to m/z 1500 throughout 
the entire separation. Masslynx software was used to process the 
mass spectral data and produce both total ion chromatograms and 
single ion recording chromatograms for the key masses of interest. 
DMB-DP3 purification by anion exchange chromatography 
Separation was achieved using a DNAPac PA-100 analytical anion 
exchange column (25 cm x 4 mm, packed with 0.1 µM microbeads, 
Dionex, UK). 
DMB fluorescence was monitored with a fluorescence detector (RF-
10A) as described above. The mobile phases used were: distilled 
water (mobile phase A) and ammonium acetate buffer (5 M, pH 7.4, 
mobile phase B) for 30 minutes and 1 ml/min flow rate, with the 
gradient outlined in Supplementary Data, Table 1.  
Measurement of polyST enzyme activity 
Recombinant human polyST (ST8SiaII) enzyme (250 ng/µl final 
concentration) was incubated at 25°C overnight in a solution of 
DMB-DP3 (10 to 100 µM), MgCl2 (5 mM), CMP-Neu5Ac (0.5 mM) 
and sodium cacodylate buffer (0.1 M, pH 6.7). Aliquots were taken 
after 1, 2, 4, 6 and 24 hours and the reaction was stopped by 10-
fold dilution with Tris-HCl (100 mM, pH 8.0), EDTA (5 mM), followed 
by centrifugation at 10,000 g for 10 minutes at 4°C. 
Analysis of polyST enzyme activity using anion exchange HPLC 
system 
Separation was achieved using a DNAPac PA-100 analytical anion 
exchange column as described previously. The mobile phases used 
were: distilled water (mobile phase A) and ammonium acetate (0.5 
M, pH 7.4; mobile phase B) with flow rate of 1.2 (ml/min) and the 
solvent gradient outlined in Supplementary Data, Table 2. 
Analysis of polyST enzyme activity using reversed phase HPLC  
Reversed phase chromatography was performed at 1 ml/min with 
ammonium formate (5 mM, pH 6, mobile phase A) and 100% 
methanol (mobile phase B). The elution of DMB-DP3 was performed 
with an isocratic method of 20 % mobile phase B over 6 minutes. 
The separation was monitored by both photodiode array (Waters 
2996) and fluorescence detector (RF-10A) as described above.  
Western blotting for PolySia-NCAM 
Samples were prepared by incubating NCAM (2.5 ng/µL) with 
human polyST (ST8SiaII) enzyme (12.5 ng/µl) suspended in 
manganese chloride (10 mM) and sodium cacodylate buffer (10 
mM, pH 6.7) for five minutes at 37°C. The reaction then was started 
by adding CMP-N-acetylneuraminic acid (CMP-Neu5Ac, 10 mM) and 
incubated at 37°C for 30 minutes. A negative control was prepared 
without polyST enzyme. 
Samples were resolved on 6% polyacrylamide gels and blotted onto 
PVDF membranes (Amersham). Non-specific antibody binding was 
blocked via incubation with skimmed milk (0.05 g/ml) and the blot 
was probed with anti-polySia antibody mAb 735 (obtained as a kind 
gift from the Gerardy-Schahn group; 1:3000 dilution) overnight at 
4°C. Antibody reactivity was detected by horseradish peroxidase 
(HRP)-conjugated antibody and chemiluminescence using ECL-Plus 
(Amersham). 
Results and discussion 
Optimisation of the DMB labelling conditions for DP3  
DP3 labelling was performed as described previously.
44
 Three 
different incubation conditions for DP3 labelling with DMB have 
been previously published
28, 45
 but have never been compared. In 
order to investigate the optimum conditions, reaction mixtures 
were each incubated for 30 minutes at 50°C, 24 minutes at 4°C and 
48 minutes at 4°C. It was found that opting for labelling conditions 
of 30 minutes at 50°C instead of 48 or 24 hours at 4 °C not only 
reduced the time required for DMB-DP3 labelling, but also 
improved efficiency, delivering a final yield of approximately 85 ± 
6% by mass after purification. This follows reversal of lactonisation 
(MW 988.3) into the unlactonised form (MW 1006.3), as described 
below. This represents a significant improvement over previously 
published studies that reported yields of only 38%.
44
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Optimisation of the DMB-DP3 purification methodology  
Two different HPLC methods were used to obtain DMB-DP3 of high 
purity: RP-HPLC and anion exchange-HPLC. These methodologies 
were chosen for the purification of DMB-DP3 after evaluation of the 
impurities was performed using LC-MS (Figure 2). 
It was found that the impurities were mainly: sialic acid monomer 
(DP1, molecular weight 309.2), DMB-DP1 (molecular weight 424.3) 
and DMB-DP3 [-H2O] (molecular weight 988.3, DMB-DP3 [-H2O] is 
the lactonised form of DMB-DP3 reported previously
46
). These 
impurities possess different polarity and charge, which allows both 
RP- and anion exchange-HPLC system to separate them effectively.  
RP-HPLC purification 
Three methods were utilised in order to determine the optimum 
conditions for DMB-DP3 purification using RP-HPLC (Supplementary 
Data, Table 3). The purification of DMB-DP3 dissolved in distilled 
water (1 µl DMB-DP3: 1000 µl water) was achieved first by RP-HPLC 
where the mobile phases used were: 1% methanol, 0.01% formic 
acid (pH 3.5) (mobile phase A) and 55% methanol, 0.01% formic 
acid (mobile phase B). The peaks were analysed by mass 
spectrometry. Both lactonised and non-lactonised forms of DMB-
DP3 were detected (see Figure 2B). 
Lactonisation of sialic acids and oligomers has been previously 
reported in more than one study
46, 47
 and has been attributed to 
acidic conditions (Figure 2A). In order to prevent this lactonisation 
with DMB-DP3, the pH of the mobile phase was increased: mobile 
phase A was modified from 1% methanol, 0.01% formic acid (pH 
3.5) to ammonium formate buffer (pH 6). However, observed 
lactonisation of DMB-DP3 was not sufficiently improved using these 
conditions (Figure 2C). 
Increasing the pH further by changing mobile phase B from 55% 
methanol, 0.01% formic acid (pH 5.8), to 55% methanol only (pH 
7.2) and changing the method from 15% B to 10% B for better 
chromatographic separation proved successful. These conditions 
successfully minimised DMB-DP3 lactonisation (as calculated by % 
peak area of lactonised form compared to the total peak area). 
While lactonisation was not completely suppressed, it did result in a 
more efficient separation (Figure 2D). A single fraction containing 
the DMB-DP3 product was collected between 11 and 15 minutes. 
Fractions from several injections were pooled and freeze-dried. The 
purified DMB-DP3 was dissolved in water to create a 200 µM 
solution and stored at -20°C. Analysis of the material using MS-HPLC 
and FD-HPLC revealed compound purity of ≥99%, representing a 
significant improvement. 
 
Figure 2.  DP3 lactonised forms and different methods used for the 
purification of DMB-DP3. (A) Structure of non-lactonised alpha-2,8-
linked sialic acid trimer 1, 1-monolactone trimer 2, 2-monolactone 
trimer 3, and di-lactone trimer 4; (B) System 1, mobile phase A: 1% 
methanol, 0.01% formic acid (pH 3.5) and mobile phase B: 55% 
methanol, 0.01% formic acid (pH 5.8); (C) System 2, mobile phase A: 
Ammonium formate buffer (pH 6) and mobile phase B: 55% 
methanol, 0.01% formic acid (pH 5.8); (D) System 3, mobile phase A: 
ammonium formate buffer (pH 6) and mobile phase B: 55% 
methanol (pH 7.2). 
 
Anion exchange-based HPLC purification 
DMB-DP3 purification using anion exchange-HPLC was initially 
performed using the methodology outlined in Supplementary Data, 
Table 4. Three peaks were detected by fluorescence (emission λ, 
448 nm). DMP-DP3 was determined to be a peak with a retention 
time of 9.42 min (data not shown), as confirmed by comparison 
with a standard. As the mobile phase used in the anion exchange 
HPLC methodology was not MS-compatible (5 M ammonium 
acetate), DMB-DP3 identity was not confirmed directly by mass 
spectrometry. 
Although the product peak appeared well resolved when using 
fluorescence detection and photodiode array detection at 373 nm 
(Figure 3A), when examined by the photodiode array detector at 
303 nm (Figure 3B), it emerged that the peak representing DMB-
DP3 was in fact two merged peaks. 
In order to resolve these peaks, the methodology was modified as 
described in the experimental section (Supplementary Data, Table 
1), which proved successful. The product from the peak 
representing DMB-DP3 (13.8 min, Figure 3D) was collected from 
several injections and freeze-dried. The solid material was analysed, 
confirmed as pure (Figure 3E), weighed and dissolved in distilled 
water to create a 200 µM solution and stored at -20 °C. 
Two different methodolgies were explored in order to determine 
the optimum method of purification. Although RP-HPLC purification 
resulted in ≥ 99% pure compound, a 45 minute method was 
required. Utilising anion exchange HPLC enabled use of a method 
requiring only 30 minutes per injection and was thus ultimately 
preferable. 
 
(A) (B) 
(C) (D) 
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Figure 3. Purification of DMB-DP3 using anion exchange HPLC. The 
peak initially identified as DMB-DP3 by fluorescence detection, as 
analysed by photodiode array at 373 nm (A) and 303 nm (B), 
revealing two peaks in the latter. Modifying the FD-HPLC method 
that resulted in merged peaks (C) to the gradient described in 
Supplementary data, Table 4, enabled complete separation of the 
two merged peaks (D). (E) Purified DMB-DP3 as observed by anion 
exchange FD-HPLC. 
 
Optimisation of the polyST enzyme reaction with DMB-DP3 
To determine enzyme activity, human polyST (ST8SiaII) was 
incubated with DMB-DP3 and the product was detected by anion-
exchange HPLC, as described in the experimental section. The 
results were compared with a negative control (i.e. without 
enzyme). 
Following polysialylation of DMB-DP3 in the presence of polyST, a 
range of polymer chain lengths (DP) of polySia could be expected. 
The reaction conditions were adjusted and optimised in order to 
maximise production of DMP-DP4, i.e. only one sialic acid monomer 
unit extension. This was desirable to allow for easier detection and 
data analysis, and to ensure the reliability and reproducibility of the 
assay. It was found that incubating polyST with DMB-DP3 for 24 
hours, showed significant increase in the yield of DMB-DP4 product 
over 2 hours incubation yield (Figure 4A). 
To determine the optimum temperature for enzyme activity, 
human polyST (ST8SiaII) was incubated with DMB-DP3 at 15, 25, 37 
and 50°C. Interestingly, incubating the reaction at 25°C resulted in a 
higher production of DMB-DP4 (Figure 4B) than at 37°C (i.e. normal 
body temperature). This was noted previously with bacterial and 
murine polyST enzymes.
45
 Clearly the conditions and buffers used 
to perform the reaction in vitro are different to the situation in vivo. 
Further optimisation was performed by incubating polyST with 
different concentrations of DMB-DP3 (10 -100 µM) and detection of 
the product DMB-DP4 after 2 and 24 hours. There was no 
significant advantage of increasing the DMB-DP3 above 20 µM 
(Figure 4A).  
As mentioned previously, it was observed that under all conditions, 
samples gave a higher yield of DMB-DP4 after 24 hours of 
incubation with polyST. This could be explained by minimisation 
and/or reversal of the lactonisation of DMB-DP3, which leads to a 
product not accepted by polyST, after incubation with sodium 
cacodylate buffer (pH 6.7). 
In an attempt to improve the yield of DMB-DP4 without the need 
for a lengthy 24 hour incubation, purified DMB-DP3 was pre-
incubated for 1 hour at 37°C in cacodylate buffer (pH 6.7) in order 
to ensure the equilibrium was shifted towards formation of the 
desired form of DMB-DP3 prior to starting the reaction with polyST. 
This protocol showed considerably higher efficiency than that 
previously observed (Figure 4C). To confirm that the improvement 
in polysialylation efficiency was indeed caused by pre-incubation of 
DMB-DP3 (and thus minimisation of lactonisation of DMB-DP3), the 
polysialylation of DMB-DP3 purified by RP-HPLC, anion-exchange 
HPLC or purified by both systems was similarly pre-incubated and 
the results were compared to that without a pre-incubation step 
(Figure 4C). It was found that equilibration is crucial. 
The reduction in polysialylation reaction efficiency associated with 
DMB-DP3 lactonisation could be explained by the relative inability 
of polyST to incorporate new sialic acid monomers within the 
lactonised structure. Human polyST catalyses the reaction between 
an incoming sialic acid residue and DMB-DP3. The 2-position of the 
incoming sugar (in the form of CMP-sialic acid) is glycosylated to the 
8 position of the non-reducing terminal sugar of DMB-DP3. In 
lactonised DMB-DP3 these positions are involved in lactone ring 
formation (Figure 2A). 
Optimisation of the assay: DMB-DP4 product quantification 
In order to accurately quantify the DMB-DP4 produced by the 
reaction of DMB-DP3 and polyST, DMB-DP4 was synthesised and 
purified utilising methodology similar to that employed for DMB-
DP3. A calibration graph was constructed (quantity DMB-DP4 
produced vs peak area, figure 4D).  
Analysis of polysialylation reaction kinetics, assay sensitivity and 
product stability  
PolyST activity was determined by incubating the enzyme with the 
substrate (CMP-Neu5Ac) and varying amounts of DMB-DP3 
acceptor. The assay kinetic parameters (Km, Vmax) were then 
calculated. The Km value of the DMB-DP3/STX reaction was 
calculated from a Lineweaver-Burk plot (Figure 5A). The experiment 
was repeated three times and the average Km value was calculated 
as 29.5 ± 3.0 µM. The Vmax value of the reaction (14.8 ± 2.7 
µmol/min/mg) was also calculated using the same plot. These 
values are consistent with those observed previously
28
 and serve to 
validate the new assay. 
In order to determine assay sensitivity and suitability for 
determination of polyST inhibition, enzyme activity, as measured by 
DMB-DP4 product formation, was assessed in the presence of 
varying concentrations of the polyST inhibitor, CMP (Sigma-Aldrich, 
UK). The quantity of DMB-DP3 acceptor was maintained at a 
constant level. It was found that a direct relationship between 
inhibitor concentration and the degree of DMB-DP3 polysialylation 
could be established, and that even small changes in inhibitor 
concentration proved detectable by analysis of product formation 
(Figure 5B). In order to determine the inhibition constant (Ki) value 
for CMP, three concentrations of CMP were used (20, 50 and 150 
µM) and a control (no CMP). Each concentration was assessed in 
the presence of different concentrations (250, 425 and 500 µM) of 
CMP-Neu5Ac (substrate). 
(A)
(B)
(C)
(D)
(E)
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Figure 4. Optimisation of the DMB-DP3 reaction with human polyST 
enzyme. (A) Optimisation of the DMB-DP3 concentration and 
duration of incubation with polyST shows no significant difference 
between the 20 and 100 µM DMB-DP3, but incubating the enzyme 
for 24 hours instead of 2 hours showed significant increase in DMB-
DP4 yield; (B) Incubation of DMB-DP3 with human polyST showed 
that 25 °C incubation temperature is optimum; (C) incubation of 
human polyST with DMB-DP3 purified by RP-HPLC, anion exchange 
HPLC or both techniques combined with incubation of the purified 
DMB-DP3 for 1 hour at 37°C in sodium cacodylate buffer (pH 6.7) 
compared to incubation of human polyST with DMB-DP3 purified by 
RP-HPLC without incubation in sodium cacodylate buffer. The 
results show that the efficiency of polysialylation of DMB-DP3 
depends on the reversal of lactonisation of the DMB-DP3, achieved 
by a pre-incubation step rather than purification technique. (D) 
Calibration graph for DMB-DP4 quantification. 
 
The Ki value was determined by constructing a Dixon plot, which 
additionally confirmed competitive inhibition, as indicated by the 
location of the intercept. The experiment was repeated three times; 
the average Ki value was measured as 12 µM (Figure 5B). Once 
more, this value is consistent with the results published previously
28
 
and serves to validate the new optimised assay. 
Optimisation of chromatography for high-throughput analysis 
For ultimate utility as a compound screen for identification of novel 
polyST inhibitors, high-throughput analysis is an essential 
requirement. In order to achieve this, further optimisation was 
performed by utilising RP-HPLC, as described in the experimental 
section.  
Using these conditions, DMB-DP4 eluted at 3.9 minutes while DMB-
DP3 eluted at 5.9 minutes. The methodology was repeated six times 
independently to ensure its reproducibility (Figure 5C), which was 
confirmed. 
RP-HPLC allowed for rapid, sensitive and reproducible analysis, due 
to the fact that the column needs no time for equilibration between 
runs: the method is isocratic, rather than the gradient elution used 
with anion exchange chromatography. The short retention times 
and excellent resolution allow for rapid analysis (less than 10 
minutes) per sample. Another advantage of using RP-HPLC is the 
ability to conjugate it to mass spectrometry, which allows very 
specific product characterisation and molecular weight information. 
Analysis of DMB-DP4 product stability 
High-throughput analysis of large numbers of polyST inhibitors will 
potentially mean large numbers of HPLC samples for analysis, which 
could thus potentially remain in an HPLC machine for prolonged 
periods. In this event, the stability of the DMB-DP3 acceptor and 
DMB-DP4 product over this lengthy period are crucially important. 
Stability of DMB-DP3 and DMB-DP4 were evaluated over a 48 hour 
period at room temperature. It was determined that both DMB-DP3 
and DMB-DP4 are stable under these conditions in the context of 
the assay (Figure 4D, 4E). 
Analysis of the assay limit of detectability 
In order to determine the limit of detection of the product DMB-
DP4 (smallest peak area that is distinguishable peak from baseline) 
produced in the DMB-DP3 polysialylation reaction, different 
concentrations of standard DMB-DP4 were injected (1 – 50 nM).  
The peak area corresponding to each concentration was recorded 
and plotted against the DMB-DP4 concentration. It was found that 
using the previously described optimised conditions, a 
concentration of 1 nM of DMB-DP4 could be detected (which is 
1/10,000 of the concentration of DMB-DP3 added) (Figure 5F). 
Analysis of assay reproducibility  
In order to assess assay reproducibility and reliability, seven 
independent control samples using the same concentration of 
DMB-DP3, polyST enzyme and CMP-Sia substrate were analysed. 
The percentage of the product DMB-DP4 was calculated (relative to 
the total peak area) and the standard deviation and coefficient of 
variation were calculated.  
It was found that the results were reproducible with an average of 
7.8% conversion of DMB-DP3 into DMB-DP4 and standard deviation 
of 0.58 and coefficient of variation of 0.07, meaning the results 
were reproducible. 
Validation of the assay 
CMP was utilised in order to validate the developed high 
throughput cell-free assay by evaluating its effect on polySia 
synthesis using both the developed assay and previously described 
western blot analysis.
28
  
 
The average product (DMB-DP4) formation relative to control 
sample after treatment with different concentrations of CMP was 
calculated using the developed assay and compared with the results 
of western blot analysis. According to the results obtained from this 
assay, it was found that 250 μM CMP resulted in 70% inhibition of 
polySia synthesis as measured by the developed assay and 74% as 
measured by western blot (using imageJ software for western blot 
quantification, Figure 6). This demonstrates concordance between 
the two assays. 
 
 
 
 
 
 
 
(A) 
(C) 
(B) 
(D) 
y = 162752x 
R² = 0.9994 
0
10
20
30
40
50
60
70
80
90
0 20 40 60
P
e
a
k
 a
re
a
 D
M
B
-D
P
4
s
ta
n
d
a
rd
 
x
1
0
0
0
0
 
Concentration (nM) 
  
6 |  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Analysis of assay kinetics and optimisation of the chromatography to 
allow high throughput-HPLC analysis. Lineweaver-Burk plot (A) and Dixon plot (B). Km of DMB-DP3 for ST8SiaII (derived from x axis 
intercept, Lineweaver-Burk plot) was calculated as 29.5 ± 3.0 µM and Vmax value (calculated from y axis intercept) was calculated as 14.8 ± 
2.7 µmol/min/mg. The Ki value of CMP was calculated from the Dixon plot. Graph lines converge above the x axis; where they intersect is -
Ki. Data points are from a single determination representative of three independent experiments. (C) The reproducibility of the results 
when running 6 samples of standard DMB-DP3 and DMB-DP4 consecutively. The first peak at 3.9 minutes represents DMB-DP4 while the 
second peak at 5.9 minutes represents DMB-DP3, the last chromatogram shows DMB-DP3 only. (D) Stability of DMB-DP4 and (E) DMB-DP3. 
The experiment was carried out by incubating DMB-DP3 and DMB-DP4 at room temperature for 48 hours. 10 µl of the sample at T0 was 
analysed using HPLC, then similar volumes of sample were analysed at regular intervals over 24h, then again at 48h. Peak area was 
measured and percent peak area compared to T0 was calculated and plotted. The experiment was repeated three times and the standard 
deviation was determined. (F) Limit of detectability of DMB-DP4 standard. 
Conclusion 
 
This study describes the development of the first reliable, sensitive, 
reproducible, cost-effective and high-throughput technique for 
quantitative analysis of human polyST activity. Furthermore, the 
protocol for synthesis and purification of DMB-DP3 has been closely 
optimised to allow large scale production of DMB-DP3. This assay 
offers significant advantages over previously reported techniques. It 
is the first study that allows analysis of human polyST enzymes 
using RP-HPLC combined with mass spectrometry allowing specific 
detection of polysialylation products. In addition, the assay will 
allow further opportunity to study these important polyST enzymes 
and will enable development of chemical probes to better 
understand biological processes associated with polyST activity and 
may ultimately pave the way to the development of novel 
therapeutics. 
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Figure 6. The effect of polyST inhibitor CMP on polySia biosynthesis 
as measured by both the cell-free chromatographic assay and 
western blot analysis. (A) Represents polyST inhibition using 0.25 M 
CMP, (B) represents polyST inhibition using 0.5 M CMP. lower 
chromatogram represents the control (no CMP) while upper 
chromatogram represents reaction in the presence of  CMP the 
inhibitor (C) Lane 1 represents the negative control (without polyST 
enzyme), lane 2 represents the positive control (without CMP), 
lanes 3 - 7 represent reactions with 0.1, 0.25, 0.5, 0.8 and 1 mM 
CMP respectively. The blot is representative of three independent 
experiments. 
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